Oncolytic polio virotherapy of cancer

Cancer

Volumn 120, Issue 21, 2014, Pages 3277-3286

  Brown, Michael C ^a   Dobrikova, Elena Y ^a   Dobrikov, Mikhail I ^a   Walton, Ross W ^a   Gemberling, Sarah L ^a   Nair, Smita K ^a   Desjardins, Annick ^a   Sampson, John H ^a   Friedman, Henry S ^a   Friedman, Allan H ^a   Tyler, Douglas S ^a   Bigner, Darell D ^a   Gromeier, Matthias ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

CD155; eIF4G; innate antiviral response; interferon; internal ribosomal entry site; nectin like molecule 5; oncolytic virus; poliovirus; translation

Indexed keywords

ONCOLYTIC VIRUS; POLIOMYELITIS VACCINE; POLIOVIRUS RECEPTOR; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; CANCER IMMUNOTHERAPY; CELL KILLING; CLINICAL EFFECTIVENESS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RHINOVIRUS; TARGET CELL DESTRUCTION; VIRAL TROPISM; VIRUS IDENTIFICATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; POLIOMYELITIS; VIROLOGY; VIRUS ENTRY;

HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLIOMYELITIS; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

EID: 84925020556     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28862     Document Type: Review

References (64)

1. Sweeney TR, Abaeva IS, Pestova TV, Hellen CU,. The mechanism of translation initiation on type 1 picornavirus IRESs. EMBO J. 2014; 33: 76-92.
2. Sabin AB, Boulger LR,. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand. 1972; 1: 115-118.
3. Gromeier M, Alexander L, Wimmer E,. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA. 1996; 93: 2370-2375.
4. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E,. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA. 2000; 97: 6803-6908.
5. Desjardins A, Sampson JH, Peters K, et al., Phase 1 study of an oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma [abstract]. Neurooncology. 2013; 15 (suppl 2): 107. Abstract 039.
6. Bischoff JR, Kirn DH, Williams A, et al., An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996; 274: 373-376.
7. Bergelson JM, Cunningham JA, Droguett G, et al., Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997; 275: 1320-1323.
8. Mori T, Arakawa H, Tokino T, Mineura K, Nakamura Y,. Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR. Oncol Res. 1999; 11 (11-12): 513-521.
9. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM,. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013; 105: 1059-1065.
10. Paine R 3rd, Christensen P, Toews GB, Simon RH,. Regulation of alveolar epithelial cell ICAM-1 expression by cell shape and cell-cell interactions. Am J Physiol. 1994; 266 (4 pt 1): L476-L484.
11. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M,. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 2004; 6: 208-217.
12. Mendelsohn CL, Wimmer E, Racaniello VR,. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989; 56: 855-865.
13. Takai Y, Miyoshi J, Ikeda W, Ogita H,. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008; 9: 603-615.
14. Gromeier M, Solecki D, Patel DD, Wimmer E,. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology. 2000; 273: 248-257.
15. Amano H, Ikeda W, Kawano S, et al., Interaction and localization of Necl-5 and PDGF receptor beta at the leading edges of moving NIH3T3 cells: implications for directional cell movement. Genes Cells. 2008; 13: 269-284.
16. Sloan KE, Eustace BK, Stewart JK, et al., CD155/PVR plays a key role in cell motility during tumor cell invasion and migration [serial online]. BMC Cancer. 2004; 4: 73.
17. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG,. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005; 65: 10930-10937.
18. Erickson BM, Thompson NL, Hixson DC,. Tightly regulated induction of the adhesion molecule necl-5/CD155 during rat liver regeneration and acute liver injury. Hepatology. 2006; 43: 325-334.
19. Castriconi R, Daga A, Dondero A, et al., NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009; 182: 3530-3539.
20. Masson D, Jarry A, Baury B, et al, Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001; 49: 236-240.
21. Nakai R, Maniwa Y, Tanaka Y, et al., Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 2010; 101: 1326-1330.
22. Ochiai H, Moore SA, Archer GE, et al., Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res. 2004; 10: 4831-4838.
23. Bevelacqua V, Bevelacqua Y, Candido S, et al., Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget. 2012; 3: 882-892.
24. Freistadt MS, Fleit HB, Wimmer E,. Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication. Virology. 1993; 195: 798-803.
25. Wahid R, Cannon MJ, Chow M,. Dendritic cells and macrophages are productively infected by poliovirus. J Virol. 2005; 79: 401-409.
26. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K,. Macrophages in experimental and human brain tumors. Part 1: studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg. 1979; 50: 298-304.
27. Ruffell B, Affara NI, Coussens LM,. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012; 33: 119-126.
28. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141: 39-51.
29. Dobrikova EY, Goetz C, Walters RW, et al., Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J Virol. 2012; 86: 2750-2759.
30. Hunter WD, Martuza RL, Feigenbaum F, et al., Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999; 73: 6319-6326.
31. Markert JM, Medlock MD, Rabkin SD, et al., Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7: 867-874.
32. Evans DM, Dunn G, Minor PD, et al., Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985; 314: 548-550.
33. Campbell SA, Lin J, Dobrikova EY, Gromeier M,. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J Virol. 2005; 79: 6281-6290.
34. de Breyne S, Yu Y, Unbehaun A, Pestova TV, Hellen CU,. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc Natl Acad Sci U S A. 2009; 106: 9197-9202.
35. Ochs K, Zeller A, Saleh L, et al., Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol. 2003; 77: 115-122.
36. Dobrikova EY, Broadt T, Poiley-Nelson J, et al., Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther. 2008; 16: 1865-1872.
37. Gingras AC, Raught B, Sonenberg N,. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999; 68: 913-963.
38. Nomoto A, Lee YF, Wimmer E,. The 5′ end of poliovirus mRNA is not capped with m7G(5′)ppp(5′)Np. Proc Natl Acad Sci U S A. 1976; 73: 375-380.
39. Pelletier J, Sonenberg N,. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988; 334: 320-325.
40. Merrill MK, Dobrikova EY, Gromeier M,. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J Virol. 2006; 80: 3147-3156.
41. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E,. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol. 1999; 73: 958-964.
42. Horie H, Miyazawa M, Ota Y, et al., Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells. Vaccine. 2001; 19 (11-12): 1456-1459.
43. Merrill MK, Gromeier M,. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol. 2006; 80: 6936-6942.
44. Neplioueva V, Dobrikova EY, Mukherjee N, Keene JD, Gromeier M,. Tissue type-specific expression of the dsRNA-binding protein 76 and genome-wide elucidation of its target mRNAs [serial online]. PLoS One. 2010; 5: e11710.
45. Dobrikov M, Dobrikova E, Shveygert M, Gromeier M,. Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase Cα regulates eIF4G1 binding to Mnk1. Mol Cell Biol. 2011; 31: 2947-2959.
46. Dobrikov MI, Dobrikova EY, Gromeier M,. Dynamic regulation of the translation initiation helicase complex by mitogenic signal transduction to eukaryotic translation initiation factor 4G. Mol Cell Biol. 2013; 33: 937-946.
47. Goetz C, Everson RG, Zhang LC, Gromeier M,. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol Ther. 2010; 18: 1937-1946.
48. Prestwich RJ, Errington F, Diaz RM, et al., The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009; 20: 1119-1132.
49. Kroemer G, Galluzzi L, Kepp O, Zitvogel L,. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31: 51-72.
50. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW,. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J Biol Chem. 1982; 257: 14806-14810.
51. Gustin KE, Sarnow P,. Effects of poliovirus infection on nucleo-cytoplasmic trafficking and nuclear pore complex composition. EMBO J. 2001; 20 (1-2): 240-249.
52. Dobrikov MI, Shveygert M, Brown M, Gromeier M,. Mitotic phosphorylation of eukaryotic initiation factor (eIF) 4G1 at Ser1232 by Cdk1:Cyclin B inhibits eIF4A helicase complex binding with RNA. Mol Cell Biol. 2014; 34: 439-451.
53. Lawson SK, Dobrikova EY, Shveygert M, Gromeier M,. p38alpha Mitogen-activated protein kinase depletion and repression of signal transduction to translation machinery by miR-124 and -128 in neurons. Mol Cell Biol. 2013; 33: 127-135.
54. Shveygert M, Kaiser C, Bradrick SS, Gromeier M,. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol Cell Biol. 2010; 30: 5160-5167.
55. Wilkins C, Gale M Jr,. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol. 2010; 22: 41-47.
56. Coffey MC, Strong JE, Forsyth PA, Lee PW,. Reovirus therapy of tumors with activated Ras pathway. Science. 1998; 282: 1332-1334.
57. Stojdl DF, Lichty B, Knowles S, et al., Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000; 6: 821-825.
58. Worthington M, Aaronson SA,. Interferon system in cells from human tumors and from persons predisposed to cancer. Infect Immun. 1971; 3: 424-428.
59. Desmyter J, Melnick JL, Rawls WE,. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol. 1968; 210: 955-961.
60. Augustine CK, Yoo JS, Potti A, et al., Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009; 15: 502-510.
61. Hou J, Zhou Y, Zheng Y, et al., Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell. 2014; 25: 49-63.
62. Agol VI,. Cytopathic effects: virus-modulated manifestations of innate immunity? Trends Microbiol. 2012; 20: 570-576.
63. Kato H, Takeuchi O, Sato S, et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441: 101-105.
64. Morrison JM, Racaniello VR,. Proteinase 2Apro is essential for enterovirus replication in type I interferon-treated cells. J Virol. 2009; 83: 4412-4422.